Findings from a recent phase 3b/4 study of upadacitinib support a treat-to-target strategy for dose escalation or reduction ...

While some topical herbal therapies may provide benefit for patients with AD, systemic herbal therapies do not provide significant benefit.

Arcutis Biotherapeutics Inc. (NASDAQ:ARQT) is one of the most promising stocks according to Wall Street analysts. On June 26, ...

Organon & Co. (NYSE:OGN) is one of the 13 Best Healthcare Stocks to Buy Under $10. On July 7, Organon & Co. (NYSE:OGN) announced that its VTAMA (tapinarof) cream, 1%, attained a strong recommendation ...

The AJMC® Atopic Dermatitis compendium is a comprehensive resource for clinical news and expert insights for the chronic skin condition that typically develops in early childhood.

The trial aims to assess the safety and efficacy of tralokinumab 300mg administered biweekly as a single agent.

Researchers have found in a new systematic review and meta-analysis that higher levels of environmental pollutants and ...

The antibody treatment could compete with Sanofi’s Dupixent and Eli Lilly’s Ebgylss, while offering the potential for less ...

Apogee Therapeutics, Inc.'s APG777 shows promising week-16 efficacy and dosing potential, targeting the AT market. Click for ...

New research highlights a spectrum of gluten-related skin disorders beyond dermatitis herpetiformis, urging clinicians to consider gluten sensitivity in patients with unexplained or chronic dermatoses ...

Treatment with dupilumab is associated with weight gain in about two thirds of adults with atopic dermatitis over 3-6 months, according to a retrospective study.

Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena,” the “Company”) today announced that Institutional Shareholder Services Inc.